What is ipamorelin classified as?
It is a synthetic pentapeptide researched as a growth-hormone secretagogue acting through a ghrelin/GHS-receptor-related system. That classification does not establish an approved use.
Classification: Synthetic pentapeptide growth-hormone secretagogue researched for activity at the ghrelin/GHS receptor system.
Ipamorelin is a synthetic pentapeptide studied as a growth-hormone secretagogue. The original pharmacology paper describes a peptide with activity through a GHRP-like receptor system and a degree of selectivity in the experimental assays used. “Selectivity” in that paper is a pharmacological description, not a claim that an individual product is safer, more effective, or suitable for a particular purpose.
This page is a neutral concentration calculator rather than a growth-hormone resource. It accepts the visitor’s own mass and liquid-volume entries, converts compatible mass units, and reports the arithmetic representation of an entered amount. It does not identify a salt, assess a certificate, or infer biological potency from a label.
Concentration is a relationship between the entered mass and the entered volume. A different volume changes that relationship even when the mass entry is unchanged. Syringe units report a position on a volume scale, so they cannot independently identify ipamorelin mass. Those distinctions are especially important when labels use different unit conventions.
Foundational studies examined receptor signaling and growth-hormone release in experimental models. A separate pharmacokinetic-pharmacodynamic study examined ipamorelin in healthy human volunteers. These publications are useful for describing research context, but they do not establish a universal response, product equivalence, or a clinically appropriate amount.
Research on a secretagogue concerns a biological pathway, not a promise about body composition, recovery, performance, or another outcome. The calculator does not translate receptor findings into a personal conclusion.
The record includes peer-reviewed experimental work and human pharmacology research. FDA advisory materials have considered ipamorelin in the context of bulk drug-substance nominations. Such a meeting record describes agency review; it does not grant marketing authorization or validate a visitor’s product.
Regulatory status may change and can differ between countries. As of the review date, PepLedger classifies ipamorelin as a research peptide and makes no claim of an approved indication. A visitor who needs a current legal or medical determination must consult the relevant regulator and a qualified professional.
Mass conversion uses 1 mg = 1,000 mcg. Concentration is mass divided by liquid volume. U-100 means 100 units per mL and U-40 means 40 units per mL; these are scale definitions.
A scale reading cannot be converted to mass without concentration. If the label’s unit, salt, or amount is unclear, the calculator cannot resolve that uncertainty and should not be used to guess it.
It is a synthetic pentapeptide researched as a growth-hormone secretagogue acting through a ghrelin/GHS-receptor-related system. That classification does not establish an approved use.
No. Ipamorelin and CJC-1295 are different research peptides with different pharmacological descriptions. Similar growth-hormone research context does not make them interchangeable.
It calculates concentration and the volume and syringe-scale units represented by visitor-entered values. It does not estimate biological effect or validate a product.
PepLedger does not determine or recommend an amount. It performs arithmetic using values entered by the visitor.
The same entered mass spread through a different volume produces a different mass-per-volume relationship. The calculator recomputes that relationship from the entered values.
PepLedger calculates concentration, liquid volume and syringe-scale position exclusively from the values you enter. It does not choose or recommend an amount.
View our calculation methodology and editorial standards
Last updated: September 13, 2026